Search Within

Aaron David Goldberg

Formats
  1. Meeting Abstract (71)
  2. Journal Article (32)
  3. Research Letter (6)
  4. Correspondence (4)
  5. Editorial (3)
  6. Review (2)
  7. Book Section (1)
Groups
  1. Adult Leukemia (119)
  2. Center for Hematologic Malignancies (119)
  3. Department of Medicine (119)
  4. Hematologic Malignancies, Division of (119)
  5. Hematology-Oncology Fellows (119)
  6. Weinberg Fellows (119)

More Groups

People
  1. Martin Tallman (49)
  2. Eytan Stein (43)
  3. Christopher Famulare (38)
  4. Andriy Derkach (22)
  5. Ross Levine (21)
  6. Jan Bewersdorf (20)

More People

Years
  1. 2025 (6)
  2. 2024 (20)
  3. 2023 (20)
  4. 2022 (15)
  5. 2021 (15)
  6. 2020 (15)

More Years

Publications
  1. Blood (63)
  2. Leukemia and Lymphoma (8)
  3. American Journal of Hematology (6)
  4. Blood Advances (5)
  5. Journal of Clinical Oncology (5)
  6. British Journal of Haematology (4)

More Publications

Publishers
  1. American Society of Hematology (68)
  2. Taylor & Francis Group (8)
  3. American Society of Clinical Oncology (6)
  4. John Wiley & Sons, Inc. (6)
  5. Elsevier Inc. (4)
  6. Ferrata Storti Foundation (4)

More Publishers

Results (119)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia
    Meeting Abstract

    Goldberg, A. D.; Talati, C.; Desai, P.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Sallman, D. A.; Lancet, J. E.; Roboz, G. J.; Sweet, K. L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Addition of crenolanib to induction chemotherapy overcomes the poor prognostic impact of co-occurring driver mutations in patients with newly diagnosed FLT3-mutated AML
    Meeting Abstract

    Goldberg, A. D.; Collins, R. H.; Stone, R. M.; Walter, R. B.; Karanes, C.; Vigil, C. E.; Wang, E. S.; Tallman, M. S.
    Blood (2018)

    Fulltext@MSK | Save
  • Molecular predictors and current management of minimal residual disease (MRD) following induction chemotherapy for acute myeloid leukemia (AML)
    Meeting Abstract

    Goldberg, A. D.; Famulare, C.; Devlin, S. M.; Farnoud, N.; Menghrajani, K.; Patel, M.; Cai, S.; Dunbar, A.; Epstein-Peterson, Z. D.; McGovern, E.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • AML with mutations in IDH1 and DNMT3A exhibits a distinct epigenetic signature with poorer overall survival
    Meeting Abstract

    Ahr, K.; Famulare, C.; Koche, R.; Spitzer, B.; Levine, R. L.; Tallman, M. S.; Goldberg, A. D.; Stein, E. M.; Glass, J. L.
    Blood (2018)

    Fulltext@MSK | Save
  • Clinical development of PD-1 blockade in hematologic malignancies
    Journal Article

    Pianko, M. J.; Goldberg, A. D.; Lesokhin, A. M.
    The Cancer Journal (2018)

    Fulltext@MSK | Save
  • Venetoclax combined with either a hypomethylating agent or low-dose cytarabine shows activity in relapsed and refractory myeloid malignancies
    Meeting Abstract

    Goldberg, A. D.; Horvat, T. Z.; Hsu, M.; Devlin, S. M.; Cuello, B. M.; Daley, R. J.; King, A. C.; Buie, L. W.; Glass, J. L.; Mauro, M. J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Molecular profiling in extramedullary acute myeloid leukemia reveals distinct subgroups defined by mutations in KIT and RUNX1
    Meeting Abstract

    Goldberg, A. D.; Farnoud, N.; Goldberger, C.; Patel, M.; Famulare, C.; Medina, J.; Rampal, R. K.; Levine, R. L.; Berman, E.; Zhang, Y.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Results from an ongoing phase 1 study indicate ACDT-301 (camidanlumab tesirine) is well-tolerated in patients with relapsed or refractory CD25-positive acute leukemia
    Meeting Abstract

    Goldberg, A. D.; Tallman, M. S.; Solh, M. M.; Ungar, D.; Rizzieri, D. A.; Walter, R. B.; Spira, A. I.; Chung, K. Y.; Stock, W.; He, S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Down for the count in acute myeloid leukemia
    Journal Article

    Goldberg, A. D.; Tallman, M. S.
    Blood (2016)

    Fulltext@MSK | Save